MarketPulse

Lyme disease vaccine

4 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Pfizer-Valneva Lyme Vaccine Clears Phase 3 with 70%+ Efficacy in Pivotal Trial

Pfizer and Valneva's Lyme disease vaccine demonstrates 70%+ efficacy in Phase 3 trials, advancing toward potential regulatory approval after decades without preventive options.
PFEVALNPhase 3 trialLyme disease vaccine
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Pfizer-Valneva Lyme Vaccine Shows 70%+ Efficacy, Advancing Key Development Milestone

Pfizer and Valneva's experimental Lyme disease vaccine demonstrated over 70% efficacy in Phase 3 trials for children and adults aged five and older.
PFEVALNPhase 3 trialLyme disease vaccine
GlobeNewswire Inc.GlobeNewswire Inc.··Pomerantz Llp

Valneva Plunges 37% After Lyme Vaccine Fails Phase 3 Trial; Law Firm Launches Investigation

Valneva stock plummets 37% after Phase 3 Lyme vaccine candidate fails trial; law firm investigates potential securities fraud claims.
PFEVALNsecurities fraudstock price decline
BenzingaBenzinga··Vandana Singh

Lyme Vaccine Setback: Valneva-Pfizer Trial Misses Primary Goal But Eyes Regulatory Path

Valneva-Pfizer Lyme vaccine trial misses primary endpoint but shows 73-75% secondary efficacy; Pfizer to seek regulatory approval despite setback. Valneva shares fell 35.27%.
PFEVALNstock declinePhase 3 trial